Antimüllerian hormone the assessment of the ovarian reserve and the reproductive outcome of the young patient with cancer

We discuss the basis for the growing use of AMH in assessment of the ovarian reserve across the lifespan, and its emerging role in assessment before and after cancer treatment.

Like Comment


Richard A. Anderson, M.D., Ph.D., W. Hamish B. Wallace, F.R.C.P.

Volume 99, Issue 6, Pages 1469-1475, May 2013


The accurate assessment of the ovarian reserve has long been a key goal in reproductive medicine. The recognition that serum antimüllerian hormone (AMH) provides an indirect measure of the ovarian reserve has led to its rapid adoption in assisted conception, and wide exploration of its potential across the reproductive lifespan from the neonate to the menopause. In this short review we discuss its relationship with the ovarian reserve in its varied meanings, and in various contexts. These include in childhood and adolescence, and in the assessment of the impact of cancer therapy on the female reproductive tract. These therapies can adversely impact all aspects of female reproduction, including hypothalamic, pituitary and ovarian hormonal activity, and the ability of the uterus to support a successful pregnancy.

Read the full text at:

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.